Cure My Disease

Don't miss your cure!

 Log in / Sign up

Oxygen bath for donor kidneys: a new hope for transplant success?

NCT ID NCT07779187

Disease control Sponsor: Karolinska University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether giving donor kidneys an extra oxygenated perfusion before transplantation improves their function one year later. Kidneys from donors after circulatory death are often at higher risk of injury. The study compares standard recovery with a technique that adds hypothermic oxygenated machine perfusion. Participants receive a kidney treated with one of the two methods and are followed with routine checkups, quality-of-life surveys, and a biopsy at one year to predict long-term transplant health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ex situ hypothermic oxygenated machine perfusion (HMPO2) of donor kidneys
What this could lead to
If successful, this could improve long-term kidney function and reduce complications for transplant recipients, potentially expanding the use of DCD donor kidneys.
What could go wrong
This is a randomized trial, but results may not apply to all transplant centers. The added perfusion could increase costs or complexity without clear benefit, and long-term outcomes beyond one year are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 214 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Donor kidneys: 1. All DCD donors in Sweden with consent for organ donation and where organ recovery is undertaken with NRP. 2. Kidney deemed transplantable by donor surgeon and responsible transplant surgeon (not discarded before or during procurement) Recipients: 1. All adult patients (\>18 yrs old) eligible for renal transplantation during study duration. 2. Recipient consented for surgery, matched to a DCD kidney. Exclusion Criteria: Donor kidneys: 1\. Kidney allocated outside of Sweden according to Scandiatransplant allocation rules. Recipients: 1. Paediatric patients (\<18 yrs old). 2. Participation in other clinical drug or medical devices trials. 3. Patient subject to combined transplant of kidney + other organ.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DCD kidney are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DCD kidney Kidney transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akademiska Hospital

    Uppsala, Sweden

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skåne University Hospital

    Malmö, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.